Navigation Links
ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
Date:8/19/2007

t rate of 38% after 8 weeks, including partial responses and stable disease, for patients with recurrent DIPG in this study represents a unique observation in these end-stage patients and has generated considerable interest.

More than half of the high-grade brain cancers or gliomas over-express epidermal growth factor receptor (EGFR) and for the most advanced brain cancers, glioblastoma multiforme (GBM), the level of expression is even higher. A study involving 29 adults with newly diagnosed high-grade gliomas, including both anaplastic astrocytomas (AA) and GBM, who were treated with surgery, external beam radiotherapy and nimotuzumab showed that the treatment was well tolerated, the median survival time was 17.5 months for the GBM patients, and has not yet been reached for the AA patients.

Nimotuzumab

Nimotuzumab is a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR). To date nimotuzumab has been administered to approximately 900 patients in more than a dozen clinical trials and on a compassionate basis. It has been approved in several countries and is being provided on a compassionate basis in certain countries including Canada, Germany, Australia and Japan. The drug continues to demonstrate a significantly more benign side-effect profile compared to all the other EGFR-targeting antibodies and small molecules targeting the EGF tyrosine kinase signalling pathway. The absence of any cases of severe rash to date and the very rare instances of any of the other debilitating side effects holds the prospect for nimotuzumab to become best-in-class for this important family of EGFR-targeting agents.

Nimotuzumab global development programs

Nimotuzumab is licensed to YM's majority-owned Canadian subsidiary, CIMYM BioSciences Inc., by CIMAB, S.A., the corporation representing the Centre for Molecular Immunology, which was responsible for the discovery and early development of this unique molecule. Nimotuzumab
'/>"/>

SOURCE YM BioSciences Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related biology technology :

1. Mirus granted European patent for gene therapy
2. Info security group announces first Eastern European chapter
3. EMD Biosciences partners with European biotech company
4. Third Wave lands European distribution deal, reports high earnings
5. Jellyfish partners for sales tracking technology
6. GE Healthcare partners with UNC on breast cancer imaging research
7. Manufacturing partnership will move into biotech and biomedical spaces
8. Fergus joins Baird Venture Partners, Caden Bio
9. Avolte Venture Partners reaches capital goal
10. NimbleGen partners with UK biotech firm
11. Big pharma seeks Wisconsin biotech partnerships
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... 2014 2014 Deep Research Report on ... and in-depth study on the current state of the ... report provides a basic overview of the industry, including ... and Chinese domestic market analysis are provided with a ... the market. A comparison between the international and Chinese ...
(Date:7/12/2014)... July 12, 2014 This ... reagents used in the life science industry. ... life science reagents market towards remarkable growth. ... and providers of life science reagents. , ... http://www.transparencymarketresearch.com/life-sciences-reagents-analytical-reagents.html . , The global life ...
(Date:7/11/2014)... 2014 /PRNewswire-iReach/ -- Maxim Peptide, a website that features ... solely in scientific experiments, is currently celebrating its second ... Maxim Peptide, which was created by the founders of ... updated website that now features a special deals section. ... with fascinating articles about peptide research, including a new ...
(Date:7/11/2014)... -- , Not for release, publication or distribution ... jurisdiction where to do so would constitute a violation of ... ("Shire" or the "Company") (LSE: SHP, NASDAQ: SHPG ... has held a meeting with representatives of AbbVie. ... agreement or approval of AbbVie. A further update ...
Breaking Biology Technology:2014 Nano Silver Industry in Global and China Regions Development Proposals Analysis Available at DeepResearchReports.com 22014 Nano Silver Industry in Global and China Regions Development Proposals Analysis Available at DeepResearchReports.com 3Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 2Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 3Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Shire plc - Statement re: Media Speculation 2
... SAIC-Frederick, Inc. and Biomatrica have begun ... which is becoming increasingly important in cancer research and ... therapies. The two organizations will focus on ... samples collected by pathologists in the clinic. Preserving nucleic ...
... be a magnet, and how can we control a magnet,s ... Igor Zutic, a theoretical physicist, has been exploring over many ... that magnets could revolutionize computing, forming the basis of high-capacity ... Today, in a commentary in Science , Zutic and ...
... Calif., May 26, 2011 MAP Pharmaceuticals, ... it has submitted a New Drug Application (NDA) to ... LEVADEX® orally inhaled migraine drug for the potential acute ... Headache Foundation, approximately 30 million people in the United ...
Cached Biology Technology:SAIC-Frederick and Biomatrica Collaborate to Improve Molecular Analysis in Cancer Research 2SAIC-Frederick and Biomatrica Collaborate to Improve Molecular Analysis in Cancer Research 3Chameleon magnets: Ability to switch magnets 'on' or 'off' could revolutionize computing 2Chameleon magnets: Ability to switch magnets 'on' or 'off' could revolutionize computing 3MAP Pharmaceuticals Submits New Drug Application to FDA for LEVADEX® Orally Inhaled Migraine Drug 2MAP Pharmaceuticals Submits New Drug Application to FDA for LEVADEX® Orally Inhaled Migraine Drug 3MAP Pharmaceuticals Submits New Drug Application to FDA for LEVADEX® Orally Inhaled Migraine Drug 4
(Date:7/11/2014)... TRAP" to capture the early signs of kidney failure, ... Journal of Clinical Investigation . Their new transgenic ... cellular and genetic information from a variety of solid ... for Medical Research in 2008, TRAP involves attaching a ... the cell type of interest. Scientists can then collect ...
(Date:7/11/2014)... team of researchers from The Chinese University of Hong ... of wild soybean linked to salt tolerance, with implication ... soil. This study published online in Nature Communications ... information for crop improvement. , Soybean is an important ... selection, cultivated soybeans have less genetic diversities than their ...
(Date:7/11/2014)... often develop relationships with other group members to reduce ... chacma baboons the strategy for grooming activities shows a ... published in the scientific journal Biology Letters . ... is not practiced without ulterior motives. To be groomed ... individual, while grooming another individual can provide access to ...
Breaking Biology News(10 mins):BGI reports a novel gene for salt tolerance found in wild soybean 2Baboons groom early in the day to get benefits later 2
... Indiana University neuroscientists Olaf Sporns and Christopher Honey find ... consider just background noise to be fascinating and important. ... are at rest. In this "resting state," waves of ... ever-changing patterns. Sporns and Honey's work on modeling this ...
... of someone’s stomach before and after a rather decadent meal. ... the cross-section of a virus, before and after cramming itself ... a tiny motor that pumps its DNA into the capsid—outer ... tightly coiled DNA may help phi29 inject its genetic material ...
... of most plants depends on the presence of sufficient amounts ... plants, the legumes, is partially free of this constraint thanks ... of the Rhizobium, genus, capable of fixing nitrogen from the ... plant, they trigger in the roots the formation and development ...
Cached Biology News:Modeling the restless brain 2Modeling the restless brain 3A new plant-bacterial symbiotic mechanism promising for crop applications 2A new plant-bacterial symbiotic mechanism promising for crop applications 3
PSMD1 Antibody...
Terrific Broth, 1 kg. Mixture of casein peptone, yeast extract, K2HPO4, and KH2PO4.Used at 47 g/l for E. coli growth with higher cell densities. Category: Nucleotides & Enzymes & Biochemicals, Ultrap...
... The high-performance triple quadrupole 1200L ... in today's cost-conscious environment - incorporating ... solutions for all liquid chromatography analytical ... (API) interface and the Transmission Quadrupole ...
Human beta IG-H3 MAb (Clone 348506) Keywords: BIGH3, betaIG-H3 Protein Family: Extracellular Matrix Molecules...
Biology Products: